Results of an international Intregroup randomized phase III trial of pazopanib versus placebo (AGO-OVAR16). Subgroup Analysis of toxicity and clinical outcome in the Asian and Non-Asian population

被引：0

作者：

Sehouli, J. ^{[1
]}

Harter, P. ^{[2
]}

Wimberger, P. ^{[3
]}

Rau, J. ^{[4
]}

Baumann, K. ^{[5
]}

Kurzeder, C. ^{[6
]}

Canzler, U. ^{[7
]}

Meier, W. ^{[8
]}

Hanker, L. C. ^{[9
]}

Mahner, S. ^{[10
]}

Krabisch, P. ^{[11
]}

Reiter, W. W. ^{[12
]}

Aminossadati, B. ^{[4
]}

du Bois, A. ^{[13
]}

机构：

[1] Charite, Campus Virchow Klinikum, Frauenklin, D-13353 Berlin, Germany

[2] Dr Horst Schmidt Klin, Klin Gynakol & Gynakol Onkol, Wiesbaden, Germany

[3] Univ Klinikum Essen, Klin Frauenheilkunde & Geburtshilfe, Essen, Germany

[4] KKS, Marburg, Germany

[5] Univ Klinikum Giessen & Marburg, Marburg, Germany

[6] Univ Ulm Klinikum, Univ Fraeunklin, Ulm, Germany

[7] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany

[8] Evangel Krankenhaus, Fraeunklin, Dusseldorf, Germany

[9] Klinikum JW Goethe Univ, Zentrum Frauenheilkunde & Geburtshilfe, Frankfurt, Germany

[10] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Gynakol, Hamburg, Germany

[11] Klinikum Chemnitz, Frauenklin, Chemnitz, Germany

[12] Schwerpunkt Praxis, Viersen, Germany

[13] Kliniken Essen Mitte, Klin Gynakol Onkol, Essen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：75 / 75

页数：1

共 21 条

[1] Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC): A subgroup analysis of an international intergroup trial (AGO-OVAR16)
Gropp-Meier, M.
Schmalfeld, B.
Belau, A.
Rau, J.
Richter, B.
Emons, G.
Hillemanns, P.
Lueck, H. -J.
Burges, A.
Fehm, T.
Harter, P.
Wimberger, P.
Baumann, K.
Kurzeder, C.
Canzler, U.
Meier, W.
Hanker, L. C.
Mahner, S.
Kosse, J.
Sehouli, J.
Suetterlin, M.
Zorr, A.
du Bois, A.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 69 - 69
[2] Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Jun Guo
Jie Jin
Mototsugu Oya
Hirotsugu Uemura
Shunji Takahashi
Katsunori Tatsugami
Sun Young Rha
Jae-Lyun Lee
Jinsoo Chung
Ho Yeong Lim
Hsi Chin Wu
Yen Hwa Chang
Arun Azad
Ian D. Davis
Marlene J. Carrasco-Alfonso
Bhupinder Nanua
Jackie Han
Qasim Ahmad
Robert Motzer
Journal of Hematology & Oncology, 11
[3] Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Guo, Jun
Jin, Jie
Oya, Mototsugu
Uemura, Hirotsugu
Takahashi, Shunji
Tatsugami, Katsunori
Rha, Sun Young
Lee, Jae-Lyun
Chung, Jinsoo
Lim, Ho Yeong
Wu, Hsi Chin
Chang, Yen Hwa
Azad, Arun
Davis, Ian D.
Carrasco-Alfonso, Marlene J.
Nanua, Bhupinder
Han, Jackie
Ahmad, Qasim
Motzer, Robert
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[4] Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).
Du Bois, Andreas
Floquet, Anne
Kim, Jae Weon
Rau, Joern
Maria Del Campo, Jose
Friedlander, Michael
Pignata, Sandro
Fujiwara, Keiichi
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor Raza
Monk, Bradley J.
Wimberger, Pauline
Ray-Coquard, Isabelle
Zang, Rongyu
Diaz-Padilla, Ivan
Baumann, Klaus H.
Kim, Jae Hoon
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[5] Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).
Du Bois, Andreas
Floquet, Anne
Kim, Jae Weon
Rau, Joern
Del Campo, Jose Maria
Friedlander, Michael
Pignata, Sandro
Fujiwara, Kelichi
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor Raza
Monk, Bradley J.
Wimberger, Pauline
Ray-Coquard, Isabelle
Zang, Rongyu
Diaz-Padilla, Ivan
Baumann, Klaus H.
Kim, Jae Hoon
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Efficacy of SB12 (Eculizumab Biosimilar) in Asian and Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial
Jang, Jun Ho
Lim, Soo Min
Tomuleasa, Ciprian
Oliynyk, Hanna
Lanamtieng, Theerin
Park, Jihye
Kim, Younsoo
Jung, Jinah
Russo, Paola
BLOOD, 2023, 142
[7] Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
Vergote, I
du Bois, A.
Floquet, A.
Rau, J.
Kim, J-W
del Campo, J. M.
Friedlander, M.
Pignata, S.
Fujiwara, K.
Colombo, N.
Mirza, M. R.
Monk, B. J.
Tsibulak, I
Calvert, P. M.
Herzog, T. J.
Hanker, L. C.
Meunier, J.
Lee, J-Y
Bologna, A.
Carrasco-Alfonso, M. J.
Harter, P.
GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 186 - 191
[8] Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials
Hasegawa, Yoshikazu
Kawaguchi, Tomoya
Kubo, Akihito
Ando, Masahiko
Shiraishi, Junji
Isa, Shun-ichi
Tsuji, Taisuke
Tsujino, Kazuyuki
Ou, Sai-Hong I.
Nakagawa, Kazuhiko
Takada, Minoru
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1881 - 1888
[9] The WATER study clinical results - a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP
Roehrborn, C.
Anderson, P.
Gilling, P.
BJU INTERNATIONAL, 2018, 121 : 12 - 12
[10] Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial
Urba, Susan
Hong, Ruey-Long
Hossain, Anwar M.
Cheng, Rebecca
Orlando, Mauro
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 331 - 341

← 1 2 3 →